Allarity Therapeutics, Inc.
ALLR Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$0.92
KIRA · Stoqly’s AI analyst, in plain words
- Allarity Therapeutics, Inc. had $0.3M of revenue in fiscal 2025.
- Its operating margin was −3,939.1%: of every 100 in sales, about −3,939 is left after running the business.
- Allarity Therapeutics, Inc. lost $11.2M in fiscal 2025.
- Free cash flow was −$14.8M in fiscal 2025, −4,633.8% of revenue.
- Allarity Therapeutics, Inc. returned $3.2M to shareholders in fiscal 2025.
- Allarity Therapeutics, Inc. has $14.7M more cash than debt.
Market cap
—
P/E
—
Revenue
$0.3M
Net income
−$11.2M
Free cash flow
−$14.8M
Operating margin
−3,939.1%
Allarity Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−3,509.7%
No. It lost money last year.
Does profit turn into cash?
−4,633.8%
No. It spent more cash than it brought in.
What Allarity Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Allarity Therapeutics, Inc.
- CIK
- 0001860657
Allarity Therapeutics, Inc. · ALLR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | −$1.3M | — | — | $0.0M | $0.3M |
| Net interest income | −$1.3M | — | — | — | — |
| Operating margin | 1,971.5% | — | — | — | −3,939.1% |
| Net income | −$26.6M | −$16.1M | −$11.9M | −$24.5M | −$11.2M |
| Net margin | 1,978.3% | — | — | — | −3,509.7% |
| Diluted EPS | −$4.19 | −$3,093.42 | −$10.26 | — | — |
| Cash | |||||
| Cash from operations | −$14.9M | −$16.8M | −$12.7M | −$17.4M | −$14.8M |
| Capital expenditure | — | $0.0M | $0.0M | $0.3M | $0.0M |
| Free cash flow | — | −$16.8M | −$12.7M | −$17.7M | −$14.8M |
| FCF margin | — | — | — | — | −4,633.8% |
| Share buybacks | — | — | — | $0.0M | $3.2M |
| Share count change | 94.8% | −99.9% | 29,175.0% | — | — |
| Debt and strength | |||||
| Cash and short-term investments | $19.6M | $2.0M | $0.2M | $19.5M | $14.7M |
| Debt incl. finance leases | — | $2.6M | $2.9M | — | $0.0M |
| Shareholders' equity | $18.2M | −$0.1M | −$2.8M | $11.8M | $9.8M |
| Current ratio | 1.0x | 0.4x | 0.1x | 2.1x | 2.1x |
| Interest coverage | −268.2x | −154.5x | −34.4x | −41.7x | −68.1x |
| Returns and quality | |||||
| Return on capital | — | −5,423.5% | −67,659.6% | — | — |
| Return on equity | −125.1% | −178.0% | — | −541.2% | −103.8% |
| Return on tangible equity | — | — | — | −213.0% | −114.3% |
| Piotroski F-score | — | — | 1 | — | — |
| Altman Z'' | −7.3 | −37.3 | −42.6 | −20.7 | −23.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Allarity Therapeutics, Inc. · ALLR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.92 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001860657). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.